BRCA1 and ovarian carcinoma: We have shown that PTPI may potentially be an important clinical biomarker that should be considered when treating patients with advanced BRCA1/2 mutation ovarian cancer with a PARP inhibitor, and warrants further investigation either in conjunction with or independent of conventional platinum response status.